Fixes prices of generi­cs of anti-cancer drugs at par with those in neighb­ouring countr­iesISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has notified up to 10 per cent reduction in maximum retail prices (MRP) of a number of brands. DRAP said it has reduced the prices of selected brands having high sales volume. Besides the above stated products, authority has reduced MRP of Lencentus Injection from Rs98,000 to Rs58,800, it said. Furthermore, DRAP fixed prices of generics of anti-cancer drugs namely; Erlotinib Tablets 100mg and 150mg, Geftinib Tablets 250mg and Transuzumab 600mg Injection at prices at par with neighbouring countries. DRAP is trying to bring prices of medicines down by various strategies including registering generic medicines at low prices etc.

Source: The Express Tribune February 23, 2018 05:48 UTC